Leptomeningeal inflammation in rheumatoid arthritis
Citation Manager Formats
Make Comment
See Comments

A 44-year-old man with a 20-year history of seropositive erosive rheumatoid arthritis (RA), diagnosed according to the American Rheumatology Association revised criteria,1 was referred for severe headache and partial simple motor seizures. At the time of presentation, his disease was inactive under a stable dose of methylprednisolone (8 mg/day). The neurologic examination was normal: there were no cranial nerve palsies, sensory motor deficits, gait imbalance, impairment of cognitive functions, or neck stiffness. Fundoscopy did not reveal any abnormality. The major finding on neuroimaging was a marked leptomeningeal enhancement (figure, A, C, and E). CSF analysis showed a normal opening pressure, normal cell count, and a slightly increased immunoglobulin G index; viral markers and culture studies were unremarkable. Biopsy specimen displayed necrotizing granulomatous inflammation of leptomeninges without pachymeningeal involvement (figure, G and H). IV methylprednisolone was prescribed (1 g/day for 3 days) followed by methotrexate in order to enhance immunosuppression and avoid an increase of the steroid load; favorable clinical and radiologic responses were observed (figure, B, D, and F).
Postcontrast T1-weighted MRI: abnormal leptomeningeal enhancement over the frontoparietal lobes and interhemispheric fissure before (A, C, E) and after (B, D, F) 3-month methotrexate treatment. Histopathology (G and H): necrotizing granulomas involving the leptomeninges surrounded by mononuclear inflammatory cells and focal giant cell reaction (arrow) without signs of vasculitis. Hematoxylin & eosin stains (×4, ×20).
Chronic meningitis may be due to infections, neoplasms, drugs, sarcoidosis, and autoimmune diseases.2 The involvement of meninges by inflammatory cells in RA may assume the form of leptomeningitis and/or pachymeningitis. Although the real prevalence is unknown, this condition is quite uncommon: only a few histopathologically proven cases have been described and the exact pathogenesis still remains unclear.3 Rheumatoid meningitis may develop in early or late stages as well as in active or inactive phases of the disease, and it may even precede synovial manifestations. The clinical phenotype may be heterogeneous: headache and cranial nerve palsies are usually associated with pachymeningeal invasion, whereas altered consciousness, psychiatric symptoms, sensory or motor deficits, and seizures are often the initial symptoms of leptomeningitis. CSF may reveal increased protein or lymphocytic pleocytosis, or it may be normal. Characteristic, although not specific, MRI findings include diffuse or patchy enhancement of leptomeninges and/or pachymeninges.4 The final diagnosis relies on histopathologic examination, which may display 3 different patterns: rheumatoid nodules, nonspecific meningeal inflammation, or vasculitis.5
Given the rarity of the condition, no formally established guidelines or standardized treatments are available to date. Successful treatment approaches usually include immunosuppressive therapies: corticosteroids, cyclophosphamide, azathioprine, or methotrexate have been variably recommended.6 Clinical improvements were reported with glucocorticoid treatment alone, suggesting that additional cytotoxic immunosuppressive agents may not be required in the induction phase. However, these may be useful as a steroid-sparing strategy to achieve tapering or cessation of steroids and reduce or avoid their long-term side effects. On the other hand, immunosuppressors alone might represent a potential alternative treatment option when glucocorticoids are contraindicated, as in a single case successfully managed with cyclophosphamide.7
Although rheumatoid meningitis is extremely rare, it should be taken into account when patients affected by RA, even in an inactive stage, develop signs or symptoms suggestive of CNS involvement in order to avoid treatment delay and prevent neurologic sequelae.
Acknowledgments
Acknowledgment: The authors thank Dr. Francesco Sessa (Department of Neuroradiology, University Hospital of Ancona, Italy) and Dr. Sara Zagaglia (Neurological Clinic, University Hospital of Ancona, Italy) for editing assistance.
Footnotes
Author contributions: All authors contributed to writing and editing this case study.
Study funding: No targeted funding reported.
Disclosure: S. Lattanzi, C. Cagnetti, P. Di Bella, and M. Scarpelli report no disclosures. M. Silvestrini is an associate editor for Journal of Alzheimer's Disease. L. Provincialli reports no disclosures. Go to Neurology.org/nn for full disclosures. The Article Processing Charge was paid by the Department of Experimental and Clinical Medicine, Marche Polytechnic University.
- Received June 2, 2014.
- Accepted in final form October 13, 2014.
- © 2014 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosisMartina Absinta, Luisa Vuolo, Anuradha Rao et al.Neurology, April 17, 2015 -
Review
Rheumatoid meningitisA case report and review of the literatureZhaoyi Qin, June Kim, Damian Valencia et al.Neurology: Clinical Practice, May 30, 2019 -
Review
Rheumatoid meningitisA rare cause of aseptic meningitis with frequently stroke-like episodesSimon Schuster, Hanna Braass, Christof Iking-Konert et al.Neurology: Clinical Practice, August 20, 2018 -
Resident and Fellow Section
Pearls & Oy-sters: Asymmetric meningeal involvement is a common feature of rheumatoid meningitisSeok-Jin Choi, Young Ho Park, Jin Ah Kim et al.Neurology, March 20, 2017